Kyle Todd/LinkedIn
Jun 25, 2025, 14:17
Kyle Todd Shared New White Paper Analyzing Clinical Development Trends Across 594 ADCs with 142 Distinct Targets
Kyle Todd, Founder and CEO of Zeal Oncology, shared a post on LinkedIn:
“Antibody-Drug Conjugates (ADCs): Expanding the Oncology Target Space
ADCs are no longer trailing traditional antibody therapeutics – they’re leading innovation across oncology, unlocking novel targets, and advancing through clinical development with increasingly sophisticated payloads and formats.
This white paper analyzes clinical development trends across 594 ADCs with 142 distinct targets, highlighting how ADCs are:
• Outpacing other modalities for select targets
• Pursuing targets untouched by other therapeutic classes
• Innovating beyond canonical payloads and antibody formatsDownload the full white paper below and follow Zeal Oncology for more insights across the cancer therapeutic landscape!”
More posts featuring Antibody-Drug Conjugates on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 12:37
Aug 25, 2025, 12:23
Aug 25, 2025, 11:07
Aug 25, 2025, 09:45
Aug 25, 2025, 09:09